These data support the effectiveness of tezepelumab in lowering total serum IgE in patients with perennial allergies and tezepelumab's function in TSLP inhibition for treating asthma exacerbations in patients with perennial allergies severe, uncontrolled asthma [15]. The gene discussed is IGHE; the disease is asthma.